Global state: 2. no significant clinical improvement ‐ CGI, short term (up to 12 weeks) · patients with schizophrenia
It is very uncertain whether RISPERIDONE changes global state: 2. no significant clinical improvement ‐ CGI, short… compared with PLACEBO (very low certainty).
1 finding from 1 review
Adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term (up to 12 weeks) ‐ general ‐ any significant EPS · patients with schizophrenia
RISPERIDONE may leads to higher adverse effects: 1a. extrapyramidal ‐ various effects ‐ short term… compared with PLACEBO (low certainty).
1 finding from 1 review
Clinically important change in positive symptoms · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Clinically important change in negative symptoms · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Catatonia: clinically important change in catatonia symptoms (improved at least 50% on the VAS) · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Clinically important adverse drug‐induced movement disorder effects on the central nervous system (EPS, NMS, MC) · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Clinically important adverse effects other than central nervous system or EPS · schizophrenia spectrum disorders with catatonic symptoms
1 finding from 1 review
Aggression · Disruptive behaviours in children and youths
2 findings from 1 review
Conduct · Disruptive behaviours in children and youths
1 finding from 1 review
Weight gain · Disruptive behaviours in children and youths
2 findings from 1 review
Global state: Relapse ‐ long term ‐ not measured · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Adverse events: Specific ‐ prolactin‐related ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ prolactin‐related ‐ long term It is… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Weight gain · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Specific ‐ weight increase ‐ long term It is unclear… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Adverse events: Nervous system disorders (inc. EPS) ‐ long term It is unclear how adverse events were reported · patients with schizophrenia
It is very uncertain whether RISPERIDONE DEPOT changes adverse events: Nervous system disorders (inc. EPS) ‐ long term It… compared with GENERAL ORAL ANTIPSYCHOTICS (very low certainty).
1 finding from 1 review
Mental state: clinically significant improvement in mental state ‐ long term1 ‐ not reported · patients with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
Relapse · patients with schizophrenia
1 finding from 1 review
Mental state ‐ improvement · patients with schizophrenia
1 finding from 1 review
Leaving the study early · patients with schizophrenia
RISPERIDONE DEPOT probably leads to lower leaving the study early: Any reason ‐ long term compared with ORAL QUETIAPINE (moderate certainty).
1 finding from 1 review
Adverse events: General ‐ serious · patients with schizophrenia
RISPERIDONE DEPOT showed no clear difference in adverse events: General ‐ serious Recorded at each compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review
Adverse events: Movement disorder ‐ any extra pyramidal symptom · patients with schizophrenia
RISPERIDONE DEPOT may leads to higher adverse events: Movement disorder ‐ any extra pyramidal symptom compared with ORAL QUETIAPINE (low certainty).
1 finding from 1 review